The molecule is also being tested in over 100 vaccine clinical trials. Rising QS-21 demand from the pharmaceutical industry ...

The presentation was sent to our distribution list by email, and you can also find it on gsk.com. Please turn ... from specialty medicines and the supply chain efficiencies. Despite incorporating ...

X-ELIO, a global leader in renewable energy, has signed a multi-buyer Power Purchase Agreement (PPA) with an Energize ...

AbbVie, Danaher, Vertex Pharmaceuticals, Cencora, GSK, Thermo Fisher Scientific, and Moderna are the seven Biotech stocks to watch today, according to MarketBeat’s stock screener tool. Biotech stocks ...

With technological advancements, shifting patient expectations and ongoing pressures for resilience, we face both challenges ...

In the fast-evolving landscape of supply chain management, 2025 presents a unique set of challenges and opportunities for executives. As companies navigate the complexities of global business ...

New York, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Overview: According to Dimension Market Research, the global clinical trial supply and Logistics Market is expected to reach USD 4,000.7 million by 2025 and ...

Chief Financial Officer Julie Brown noted, "Core operating margin improved to 29.2%, up 130 basis points year-on-year," driven by specialty medicines and supply chain efficiencies. GSK expects ...

Under the terms of the clinical supply agreement, Immuneering will sponsor the planned studies and Regeneron will provide Libtayo. Immuneering will maintain global development and ...

Thursday said it has signed a clinical supply agreement with Regeneron Pharmaceuticals. The supply agreement supports the evaluation of Immuneerings' lead product candidate, IMM-1-104, in ...

Experts at the 2025 Clinical Trial Supply Europe will explore supply chain challenges and the impact of AI on trials.